B. Schmetter

The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial

K. Chaloner, W. El-Sadr, D. Cohn, 2001, AIDS.

A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial

M. Kozal, K. H. Hullsiek, M. Dehlinger, 2006, The Lancet.

Evaluation of two in vitro assays to screen for potential developmental toxicants.

J C Lamb, R D Curren, V. Steele, 1988, Fundamental and applied toxicology : official journal of the Society of Toxicology.

Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy.

M. Kozal, K. Huppler Hullsiek, M. van den Berg-Wolf, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.

Gary Collins, J. Lawrence, K. H. Hullsiek, 2003, The New England journal of medicine.

A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer.

D. Lamm, N. Bander, H. Grossman, 1997, Journal of Urology.

Disadvantages of Structured Treatment Interruption Persist in Patients With Multidrug-Resistant HIV-1: Final Results of the CPCRA 064 Study

J. Lawrence, K. H. Hullsiek, D. Abrams, 2006, Journal of acquired immune deficiency syndromes.

Sustained Benefit From a Long-Term Antiretroviral Adherence Intervention: Results of a Large Randomized Clinical Trial

E. Morse, G. Friedland, J. Matts, 2006, Journal of acquired immune deficiency syndromes.

The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial.

R D MacArthur, Li Chen, M. van den Berg-Wolf, 2001, Controlled clinical trials.

Efficacy and Safety of Abacavir Plus Lamivudine Versus Didanosine Plus Stavudine When Combined with a Protease Inhibitor, a Nonnucleoside Reverse Transcriptase Inhibitor, or Both in HIV-1 Positive Antiretroviral-Naive Persons

M. Kozal, M. Dehlinger, M. van den Berg-Wolf, 2004, HIV clinical trials.